Prelude Therapeutics Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Prelude is a clinical-stage oncology company with no product revenue to date.
Financial performance and position
| Metric | Q1 2024 | Prior comparable period / date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $27.4 million | $21.8 million |
| General and administrative expense | $6.9 million | $7.3 million |
| Total operating expenses | $34.3 million | $29.1 million |
| Other income, net | $2.9 million | $1.4 million |
| Net loss | $31.4 million | $27.7 million |
| Net loss per share, basic and diluted | $0.42 | $0.58 |
| Net cash used in operating activities | $31.8 million | $30.1 million |
| Cash, cash equivalents and marketable securities | $201.9 million | $232.9 million at December 31, 2023 |
At March 31, 2024, cash and cash equivalents were $24.7 million and marketable securities were $177.2 million. Restricted cash of $4.0 million is separate. Current assets were $205.4 million versus current liabilities of $17.6 million. The filing reports no borrowings; liabilities include operating lease obligations, with a $17.6 million total recorded lease liability. No operating margin is meaningful because the company had no revenue.
Changes versus Q1 2023
- R&D expense rose $5.6 million, primarily due to the timing of clinical research programs. Program spending increased for PRT3789 ($4.2 million versus $1.4 million), PRT2527 ($2.1 million versus $1.1 million), and discovery programs ($6.7 million versus $4.2 million).
- G&A expense declined $0.3 million, mainly because of lower stock-based compensation, partly offset by higher professional fees.
- Other income increased $1.5 million, primarily from interest earned on cash and investments.
- Net loss increased $3.7 million. Loss per share declined despite the higher net loss, as weighted-average shares increased to 75.7 million from 47.7 million.
- Operating cash use increased $1.7 million. Investing activities provided $31.2 million, mainly from security maturities; financing activities used $0.01 million. Cash, cash equivalents and restricted cash decreased $0.6 million during the quarter.
Outlook, management commentary and risks
- Management expects available cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into 2026; the liquidity note separately says funds are expected to cover at least the next 12 months from the filing date. The company expects continuing losses and will need additional capital thereafter.
- Management expected to complete PRT3789 monotherapy dose escalation around mid-2024, identify recommended Phase 2 doses, and present initial Phase 1 data in the second half of 2024. Enrollment in NSCLC and other back-fill cohorts was ongoing.
- PRT7732 was in IND-enabling studies and expected to enter Phase 1 in the second half of 2024. PRT2527 development continued in hematologic malignancies, with monotherapy dose escalation expected to conclude around mid-2024 and an AML cohort expected to begin in the first half of 2024.
- Prelude discontinued PRT1419 development, prioritizing PRT2527, and intends to explore external-partner options for continued development of PRT3645. The AbCellera collaboration covers discovery and development of up to five precision antibody-drug-conjugate programs; related Q1 costs were not material.
- Clinical, regulatory, competitive, intellectual-property, financing and execution risks remain. Additional financing may dilute shareholders or require the company to delay, reduce or discontinue programs. The filing also identifies potential effects from U.S.-China tensions and trade or regulatory measures, and FCPA and Chinese anti-corruption-law exposure tied to third parties and activities in Taiwan.
- The company reported no material legal proceedings and no material changes in internal control over financial reporting. Disclosure controls were assessed as effective at a reasonable assurance level.
Important facts for investors to verify
- Whether reported clinical timelines and anticipated data releases were achieved, and the subsequent safety, activity and dose-selection results for PRT3789 and PRT2527.
- Whether the stated runway into 2026 remains achievable given quarterly cash use, future trial costs and the company’s lack of committed financing.
- Potential dilution: 20.8 million pre-funded warrant shares remained unexercised at March 31, 2024; the company also had $75.0 million remaining under its sales agreement and $187.0 million under its shelf registration statement.
- Progress, economics and development responsibilities under the AbCellera collaboration, and the prospects for external partnering of PRT3645.
- Lease and grant obligations, including the $4.0 million restricted-cash letter of credit and the potential grant repayment obligation if the company leaves Delaware within the specified period.